Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Insulin Delivery Devices Market Size & Share 2026-2035
Report ID: GMI1649
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Download Free PDF
Explore Our Licensing Options:
Download Free PDF
Insulin Delivery Devices Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Insulin Delivery Devices Market Size
The global insulin delivery devices market was valued at USD 20.00 billion in 2025, is estimated to reach USD 21.90 billion in 2026, and is projected to expand at a 7.9% CAGR (2026-2035) to USD 42.96 billion by 2035.
Insulin Delivery Devices Market Key Takeaways
Market Leader: Medtronic plc led with over 13.5% market share in 2025.
Leading Players: Top 5 players in this market include Medtronic plc, Insulet Corporation, Becton Dickinson and Company, Tandem Diabetes Care, Roche, which collectively held a market share of 39.7% in 2025.
The insulin delivery devices market is evolving from a predominantly injection-led supply market into a broader connected-care ecosystem. Automated insulin delivery (AID), digital dose support, and recurring consumable requirements are changing product mix, while reimbursement design and clinical training continue to determine how quickly advanced systems convert eligible patients into active users.
GMI Analyst View
Based on our comprehensive assessment of company revenue disclosures and direct industry engagement, the global insulin delivery devices market reached USD 18.50 billion in 2024, confirming robust pre-base momentum from rising automated insulin delivery adoption and sustained high-frequency consumable demand across major markets.
Insulin Delivery Devices Market Trends, Growth Drivers & GMI Forecast Outlook
The market's outlook rests on a widening insulin-treated population and a more clinically accessible AID proposition. Premium pumps are gaining relevance as interoperability and type 2 diabetes indications expand, while pens, needles, syringes, and infusion supplies preserve a large recurring-demand base across care settings.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Diabetes prevalence supplies a durable volume foundation because every intensification pathway requires either a delivery device, a recurring consumable, or both. The opportunity is not homogeneous: advanced systems gain traction where specialist care and reimbursement are available, whereas pens and lower-cost accessories remain the practical access point in markets with constrained coverage.
The expansion of AID eligibility into insulin-requiring type 2 diabetes changes the addressable market for pumps more materially than an incremental feature launch. Recent U.S. clearances for Omnipod 5, Control-IQ+, and MiniMed 780G extend the clinical case for automated management beyond the traditional type 1 population, placing prescribers, payer criteria, and onboarding capacity at the center of pump conversion rates [2] [3] [4].
Interoperability also shifts the competitive basis of AID from a closed hardware proposition toward an ecosystem proposition. Manufacturers that can maintain sensor compatibility, software-update discipline, and clinically credible user experiences should have greater ability to defend upgrade cycles and reduce the friction that has historically slowed switching.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Affordability is a market-shaping constraint rather than simply a patient-level barrier. Advanced systems require coverage for both the initial platform and the continuing flow of sensors, infusion supplies, and related services. Prior authorization, eligibility criteria, and channel-specific fulfillment rules can delay adoption even in well-insured populations, favoring manufacturers with established payer relationships and streamlined pharmacy or durable medical equipment pathways.
The gap between disease burden and device access is especially consequential in lower-income settings. Basic delivery formats can reach large patient populations through pharmacy and public-procurement channels, but premium pump adoption requires a combination of reliable insulin availability, specialist support, connected-device infrastructure, and sustainable payment mechanisms. Cybersecurity, post-market monitoring, and software maintenance further raise the execution threshold for companies seeking to compete in connected delivery.
GMI Analyst View
We see the forecast as a two-layer demand story: connected pumps and AID systems create the market's innovation premium, while injection supplies and pump consumables provide resilience through their recurring use. The relative pace of reimbursement expansion will determine how widely the premium layer penetrates beyond established care systems.
Insulin Delivery Devices Market Segment Analysis
By Product Type
Insulin Pumps
The insulin delivery devices market generated USD 6.50B from insulin pumps in 2025, and the segment is projected to account for 40.0% of global revenue in 2035.Pump adoption is increasingly tied to the availability of AID algorithms, sensor compatibility, patient training, and reimbursement continuity. The category's strategic value exceeds its device sale because each installed pump can establish an ongoing relationship for infusion sets, reservoirs, software support, and future upgrades.
Tubed pumps generated USD 3.50B in 2025 and are projected to reach USD 8.40B by 2035.Established clinical familiarity, broad specialist support, and expanding sensor integrations preserve the relevance of tubed systems. Their installed base gives manufacturers a practical route to transition users toward newer automation features without requiring a wholesale change in care workflow.
Tubeless/Patch Pumps
Tubeless/patch pumps represented 15.0% of global market revenue in 2025 and are projected to grow at an 11.4% CAGR (2026-2035).The absence of external tubing makes patch systems particularly relevant for users prioritizing discretion, mobility, and simpler onboarding. Their growth is also reinforced by pharmacy-oriented fulfillment models that can reduce friction relative to conventional durable medical equipment channels.
Insulin Pens
Insulin pens accounted for 38.0% of global market revenue in 2025 and are projected to reach USD 17.00B by 2035.Pens remain the most scalable intermediate step between syringes and advanced pumps. Their clinical familiarity, compatibility with diverse insulin formulations, and broad retail availability support continued relevance across both mature and price-sensitive markets.
Reusable Pens
Reusable pens generated USD 2.40B in 2025 and are projected to account for 13.7% of global market revenue in 2035.Connected reusable platforms offer a bridge between conventional injections and digitally supported diabetes management. Their appeal rests on dose-recording capability, cartridge flexibility, and compatibility with applications that support adherence and titration discussions.
Disposable Pens
Disposable pens generated USD 5.20B in 2025 and are projected to reach USD 11.11B by 2035.Pre-filled formats retain a broad role where convenience, simplified handling, and extensive pharmacy distribution outweigh the benefits of more complex connected systems. Their accessibility positions them as a primary growth vehicle in markets where pump affordability remains limited.
Other/Consumables
Other/consumables generated USD 5.90B in 2025 and are projected to grow at a 4.0% CAGR (2026-2035).This category provides the market's recurring-use foundation. Although its mix is gradually affected by faster growth in premium devices, demand remains anchored by the scale of injection-based therapy and the routine replacement requirements of pump users.
Pen Needles
Pen needles generated USD 3.00B in 2025 and are projected to reach USD 4.68B by 2035.High repurchase frequency and the size of the global pen-user base support recurring demand. Quality standards, institutional purchasing requirements, and distribution reach remain decisive competitive factors in this category.
Insulin Syringes
Insulin syringes represented 8.0% of global market revenue in 2025 and are projected to grow at a 2.5% CAGR (2026-2035).Syringes remain essential in affordability-constrained settings and clinical channels requiring flexible administration. Their slower outlook reflects a gradual shift toward pens and pumps rather than a loss of relevance in basic-access markets.
Pump Consumables
Pump consumables generated USD 900 million in 2025 and are projected to grow at a 5.7% CAGR (2026-2035).Infusion sets, reservoirs, and related supplies create a recurring revenue stream that follows pump utilization rather than only new-device placements. Reliability, supply continuity, and compatibility influence retention as strongly as the initial platform choice.
Testing Strips
Testing strips represented 2.0% of global market revenue in 2025 and are projected to reach USD 486 million by 2035.Strip demand remains linked to routine monitoring workflows, particularly where continuous glucose monitoring is not universally accessible. Its outlook is moderated by sensor adoption among patients using more advanced device-managed regimens.
By End Use
Hospitals & Clinics
Hospitals & clinics generated USD 7.00B in 2025 and are projected to account for 33.0% of global market revenue in 2035.Clinical settings remain central to diagnosis, initiation, complex titration, and acute-care insulin management. Long-term purchasing relationships and formulary processes provide revenue visibility, even as routine maintenance shifts toward outpatient settings.
Home Care
Home care accounted for 58.0% of global market revenue in 2025 and is projected to reach USD 26.87B by 2035.Home care reflects the structural movement of stable diabetes management away from institutional settings. Simpler interfaces, remote support, and growing patient familiarity with self-management tools are strengthening the role of home-based delivery and resupply.
Other (Retail/Pharmacy)
Other retail/pharmacy channels generated USD 1.40B in 2025 and are projected to grow at a 3.2% CAGR (2026-2035).Pharmacies remain important access points for consumables and basic delivery formats, particularly where community pharmacists support device selection and adherence. Channel growth is moderated as specialty distribution and home-delivery models capture a larger share of ongoing therapy needs.
GMI Analyst View
We find that value is migrating toward platforms that combine delivery, data, and replenishment rather than toward devices in isolation. Manufacturers that secure the initial user conversion can build durable commercial relationships through consumables, interoperability, and successive technology upgrades.
Insulin Delivery Devices Market Regional Analysis
North America Insulin Delivery Devices Market Analysis
The insulin delivery devices market in North America generated USD 8.80B in 2025 and is projected to account for 42.0% of global revenue in 2035.The region combines deep reimbursement infrastructure, dense specialist networks, and a concentration of leading pump innovators. Its market is shaped less by basic access than by eligibility expansion, payer policy, sensor integration, and the speed with which clinical practices can enroll patients into connected delivery programs.
U.S.
The U.S. generated USD 7.92B in 2025 and is projected to reach USD 16.22B by 2035.Regulatory activity and commercial coverage make the U.S. the primary launch market for advanced AID systems. Pharmacy benefit design, durable medical equipment rules, and direct manufacturer engagement continue to influence which platforms reach patients most efficiently.
Canada
Canada generated USD 880 million in 2025 and is projected to reach USD 1.80B by 2035.Provincial variation in pump funding and eligibility remains a defining market feature. Broader public coverage for adults and expanded reimbursement for automated systems would be the principal catalyst for more uniform national adoption.
Europe Insulin Delivery Devices Market Analysis
Europe represented 28.0% of global market revenue in 2025 and is projected to reach USD 11.01B by 2035.National health systems support a substantial installed base of insulin delivery technologies, but reimbursement assessment and price-control mechanisms create uneven adoption timing. The region rewards suppliers that can navigate country-specific evidence requirements, tender structures, and clinical pathways.
Germany
Germany generated USD 1.09B in 2025 and is projected to reach USD 2.14B by 2035.Germany's structured reimbursement environment and specialist diabetes network support adoption of advanced delivery solutions among eligible patients. Post-approval coverage decisions and provider confidence remain more consequential than initial regulatory clearance alone.
UK
The UK represented 13.6% of Europe in 2025 and is projected to grow at a 7.0% CAGR (2026-2035).NHS criteria and centralized procurement create a defined route for AID adoption, but patient access depends on implementation capacity across local care pathways. Broader hybrid closed-loop availability would strengthen demand for compatible pumps and consumables.
France
France generated USD 762 million in 2025 and is projected to reach USD 1.49B by 2035.Hospital-led initiation and community-pharmacy resupply create a supportive model for stable AID users. The market benefits when reimbursement, clinical training, and product availability move in parallel.
Italy
Italy represented 9.8% of Europe in 2025 and is projected to reach USD 1.07B by 2035.Regional variation in healthcare administration produces uneven device access across the country. Greater consistency in reimbursement criteria would improve the addressable market for both pumps and associated consumables.
Spain
Spain generated USD 437 million in 2025 and is projected to account for 7.8% of Europe in 2035.Autonomous-community reimbursement decisions shape adoption more directly than national policy alone. Early regional programs can establish clinical and procurement precedents for broader expansion.
Netherlands
The Netherlands generated USD 327 million in 2025 and is projected to reach USD 642 million by 2035.Digital-health readiness and insurer interest in outcome-linked models create a favorable setting for connected delivery systems. Continued uptake depends on demonstrating practical clinical value alongside sustainable reimbursement.
Rest of Europe
Rest of Europe represented 29.9% of Europe in 2025 and is projected to reach USD 3.30B by 2035.This group contains markets with markedly different pump maturity and reimbursement conditions. As device assessments and national coverage decisions broaden, suppliers with flexible pricing and localized service models should have a clearer route to expansion.
Asia Pacific Insulin Delivery Devices Market Analysis
The insulin delivery devices market in Asia Pacific generated USD 4.00B in 2025 and is projected to grow at a 10.5% CAGR (2026-2035).The region combines substantial diabetes demand with highly varied affordability, care infrastructure, and reimbursement conditions. Japan and South Korea offer advanced device environments, while China, India, and Southeast Asia provide large-volume opportunities that require differentiated product tiers and locally adapted channels.
China
China generated USD 1.32B in 2025 and is projected to reach USD 3.67B by 2035.Domestic capacity in basic delivery products and growing access to premium imported platforms are creating a dual-track market. Reimbursement expansion, urban specialist care, and local manufacturing will determine the balance between these pathways.
India
India represented 16.0% of Asia Pacific in 2025 and is projected to reach USD 1.78B by 2035.The market remains centered on accessible injection supplies, while pump adoption is concentrated in urban specialist settings. Broader insurance penetration and price-competitive domestic production are essential for expanding advanced-device use.
Japan
Japan generated USD 840 million in 2025 and is projected to reach USD 2.33B by 2035.National coverage and high clinical expectations support premium-device demand. An aging insulin-treated population and established diabetes-care infrastructure reinforce the market's potential for connected delivery adoption.
South Korea
South Korea represented 11.0% of Asia Pacific in 2025 and is projected to grow at a 10.5% CAGR (2026-2035).Digital-health infrastructure and a technology-oriented clinical environment support connected-device uptake. Continued reimbursement progression will be critical for translating this readiness into wider AID penetration.
Australia
Australia generated USD 440 million in 2025 and is projected to reach USD 1.22B by 2035.Support for consumables and established specialist diabetes care underpin adoption. The country's early AID use and developed clinician network support relatively active upgrade cycles.
Rest of Asia Pacific
Rest of Asia Pacific represented 8.0% of the region in 2025 and is projected to reach USD 891 million by 2035.Southeast Asian markets offer growing demand for needles, syringes, and pens, while premium pump adoption remains concentrated in private urban care. Regulatory harmonization could lower market-entry friction for suppliers expanding across the region.
Latin America Insulin Delivery Devices Market Analysis
Latin America represented 5.0% of global market revenue in 2025 and is projected to reach USD 2.47B by 2035.The region's market is primarily supported by pen and consumable demand, with advanced devices concentrated among privately insured patients and specialist centers. Public diabetes programs can widen access, but pricing and import conditions remain important constraints.
Brazil
Brazil generated USD 450 million in 2025 and is projected to reach USD 1.11B by 2035.Public procurement supports a large base of basic delivery supplies, while private coverage provides the clearest route for pump adoption. Greater physician familiarity with AID can progressively broaden advanced-device demand.
Mexico
Mexico represented 30.0% of Latin America in 2025 and is projected to grow at a 9.5% CAGR (2026-2035).Urban private insurance growth and cross-border clinical familiarity support demand for higher-value systems. Basic supplies remain the principal volume opportunity through social-security and pharmacy channels.
Argentina
Argentina generated USD 100 million in 2025 and is projected to account for 10.0% of Latin America in 2035.Specialist centers support use of advanced systems for complex patients, but currency volatility and import constraints complicate product availability and pricing. Reliable supply is a central competitive consideration.
Rest of Latin America
Rest of Latin America generated USD 150 million in 2025 and is projected to reach USD 371 million by 2035.Expanding private coverage and urban diabetes-care infrastructure support gradual adoption across several markets. Public programs are likely to remain centered on basic consumables over the near term.
Middle East & Africa Insulin Delivery Devices Market Analysis
The Middle East & Africa generated USD 600 million in 2025 and is projected to grow at a 9.0% CAGR (2026-2035).Gulf health investment and rising specialist-care capacity support device uptake in the region's higher-income markets. Elsewhere, affordability, insulin availability, and supply-chain reliability constrain adoption largely to basic delivery supplies.
Saudi Arabia
Saudi Arabia generated USD 180 million in 2025 and is projected to reach USD 427 million by 2035.Government-funded healthcare and investment in chronic-disease management provide a foundation for broader access to diabetes supplies. Local distribution partnerships remain important for extending advanced-device availability.
UAE
The UAE represented 20.0% of MEA in 2025 and is projected to grow at a 9.0% CAGR (2026-2035).A sophisticated private-care sector and internationally connected specialist centers support early adoption of premium AID systems. The country's role as a regional healthcare hub also strengthens its importance for supplier market-entry strategies.
South Africa
South Africa generated USD 90 million in 2025 and is projected to reach USD 214 million by 2035.Private insurance and specialist care support the region's most developed sub-Saharan market for insulin delivery devices. Advanced-device access remains concentrated, but the country provides a potential base for broader regional commercial development.
Rest of MEA
Rest of MEA generated USD 210 million in 2025 and is projected to account for 34.9% of MEA in 2035.Market conditions range from Gulf procurement systems with expanding device access to sub-Saharan settings where basic insulin supply remains the priority. Suppliers will need materially different pricing, distribution, and service models across these markets.
GMI Analyst View
We expect Asia Pacific to provide the market's most consequential growth opportunity because it combines expanding healthcare expenditure with a large diabetes treatment base. North America should retain revenue leadership, but localized portfolios and access strategies will increasingly determine where incremental industry value is created.
Insulin Delivery Devices Market Share & Competitive Landscape
The global insulin delivery devices market is moderately concentrated, with the top five manufacturers, Medtronic plc, Insulet Corporation, Becton Dickinson and Company (BD), Tandem Diabetes Care, and Roche, collectively accounting for 39.7% of total market revenue in 2025. Their strong market positions are supported by established insulin delivery portfolios, continuous product innovation, extensive distribution networks, and broad access across key diabetes care markets worldwide.
Recent Industry Developments
In December 2025, Medtronic began the U.S. commercial launch of its MiniMed 780G system with the Instinct sensor. The launch followed FDA clearance supporting interoperability and use in insulin-requiring type 2 diabetes, advancing Medtronic's strategy to expand the system's clinical and sensor-integration reach [6].
In 2026, Insulet received FDA 510(k) clearance in December 2025 for Omnipod 5 algorithm enhancements, including a lower glucose-target option. The update strengthens the company's clinical performance positioning in tubeless AID and is intended for U.S. commercialization. [7].
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →